Categories Technology

Alphabet’s Verily teams up with ResMed to tackle sleep apnea

The healthcare-based subsidiary of Alphabet (GOOGL), Verily, and medical equipment company ResMed (RMD) will join forces to form a JV that will focus on the treatment of sleep apnea and other sleep-related breathing disorders. The partnership aims to create a software that helps in detecting, diagnosing and treating the potentially serious types of sleep disorders.

Verily has entered into several partnerships ever since it became an independent subsidiary of Alphabet in 2015, including pharma giants Johnson & Johnson (JNJ), Sanofi, and Gilead Sciences (GILD). Verily now aims at getting more initiatives into hospitals. Hence, the unit has strengthened its leadership team and has appointed several industry experts to its Board.

The latest JV will combine ResMed’s sleep expertise and Verily’s advanced health data analytics technologies to study the health and financial impacts of undiagnosed and untreated sleep apnea. ResMed has spent years researching sleep apnea, which is a significant health issue in the US. This disorder is said to affect nearly 22 million Americans, most of which remain undiagnosed.

Related: Google’s research firm outstrips pharma rivals in heart disorder prediction

Verily has several promising ongoing projects including controlling the spread of Zika virus, developing glucose-monitoring contact lenses, creating wristbands that helps spot indicators of cancer and heart diseases and many more.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top